



Tygacil[®] (tigecycline) – First-time generic

- On November 30, 2017, Sandoz launched an [AP-rated](#) generic version of [Tygacil \(tigecycline\)](#) injection.
- Tygacil is indicated for the treatment of complicated skin and skin structure infections, complicated intra-abdominal infections, and community-acquired bacterial infections caused by susceptible isolates of certain bacteria.
 - Consult Tygacil's drug label for information about susceptible isolates for each indication.
 - Tygacil is not indicated for the treatment of diabetic foot infections.
 - Tygacil is not indicated for the treatment of hospital-acquired or ventilator-associated pneumonia.
- Tygacil carries a boxed warning for all-cause mortality.



OptumRx[®] specializes in the delivery, clinical management and affordability of prescription medications and consumer health products. We are an Optum[®] company — a leading provider of integrated health services. Learn more at [optum.com](#).

All Optum[®] trademarks and logos are owned by Optum, Inc. All other brand or product names are trademarks or registered marks of their respective owners.

This document contains information that is considered proprietary to OptumRx and should not be reproduced without the express written consent of OptumRx.

RxNews[®] is published by the OptumRx Clinical Services Department.

©2017 Optum, Inc. All rights reserved.